Product
Xanomeline and Trospium Chloride
Aliases
KarXT, Xanomeline and Trospium Chloride Capsules
4 clinical trials
1 indication
Indication
SchizophreniaClinical trial
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaStatus: , Estimated PCD: 2026-02-01
Clinical trial
A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 SchizophreniaStatus: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaStatus: Recruiting, Estimated PCD: 2025-02-01